With the rising number of liquid biopsy approvals and investments, their potential for early disease detection, real-time monitoring, and personalized treatment has become increasingly evident.

The inaugural Liquid Biopsy for Precision Medicine Summit Europe has been established to delve into critical challenges including biomarker selection, clinical validation, market access, commercialization, and regulatory harmonisation to bring personalized medicine to patients faster, trailblazing a path for liquid biopsies to be effectively implemented into clinical trials across Europe. This end-to-end forum delves deep into liquid biopsy development, offering exclusive insights on how to overcome critical issues including:

• Discover how to use liquid biopsies to monitor treatment responses more efficiently and guide dose selection decisions to remove patient burden with insights from Bayer 
• Understand and define early on in development what the correct biomarkers, or a signature that can be used in conjunction with the drug with insights from Roche
• Navigating European diagnostic regulations to expedite approvals and commercialisation for easier market access with insights from Step Pharma and Janssen Pharmaceuticals 
• Leveraging learnings from oncology to neuroscience and rare disease to provide more personalised treatment options for patients and improved patient outcomes with the Brain Tumour Research Centre of Excellence and TauRx Therapeutics 

This event is the end to end most comprehensive event for the liquid biopsy community in Europe, where you will join 60+ Heads, VPs and Directors of Translational Medicine, Precision Oncology, Companion Diagnostics and more to contribute to the field’s advancements, support commercialization, and market access to improve disease diagnosis, monitoring, and treatment options to improve patient outcomes.